AlphaStocks
5.3
Consider Buy

Argenx SE (ARGX)

As of Sep 19, 2026, Argenx SE (ARGX) scores 5.3/10 on AlphaStocks' five-model composite, #89 of 168 Health Care stocks. At $992, ARGX trades 97% above its model fair value of $504.

Health Care

ADR

$991.83

Below average on several measures. Research carefully.

Consider Buy

Score based on 3 of 5 models — moderate confidence

Data as of Sep 19, 2026

#89out of 168 in Health Care

Is ARGENX SE a Good Investment in 2026?

ARGENX SE (ARGX) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model is the most favorable, rating ARGENX SE as Neutral. However, the Graham model rates it Caution — Significantly above fair value. ARGENX SE currently trades 97% above its estimated fair value of $504. ARGENX SE ranks #89 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E50.7ROE19.3Market Cap65B

Estimated Fair Value

$504.0697% above

Trading above estimated fair value. P/e of 51x implies high growth expectations. rapid eps growth (53%) partially justifies the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Neutral

4/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is ARGENX SE (ARGX) a good investment?
As of Sep 19, 2026, Argenx SE (ARGX) scores 5.3/10 on AlphaStocks' five-model composite, #89 of 168 Health Care stocks. At $992, ARGX trades 97% above its model fair value of $504. That score is below average, suggesting caution.
What is ARGENX SE's Piotroski F-Score?
ARGENX SE's Piotroski F-Score status is Neutral. The raw score is 4/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ARGX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $504, ARGX appears overvalued. The stock currently trades 97% above its estimated fair value. Trading above estimated fair value. P/e of 51x implies high growth expectations. rapid eps growth (53%) partially justifies the premium.
How does ARGX compare to other Health Care stocks?
ARGENX SE ranks #89 out of 168 stocks in the Health Care sector, placing it in the top 53% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ARGX?
AlphaStocks evaluates ARGX using five proven investment models. Piotroski: Neutral; Buffett: Neutral; Graham: Caution. These models are combined into a single composite score of 5.3/10.

Similar Stocks

INSPABBVINCY

Compare ARGX with

ARGX vs INSPABBV vs ARGXARGX vs INCYARGX vs VAL

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer